Inflammatory Markers for Guiding Immunomodulation in TEN
Currently, there are no established inflammatory markers routinely used to guide immunomodulatory therapy in toxic epidermal necrolysis according to the UK guidelines, though emerging research suggests several promising biomarkers that may help predict treatment response and disease severity. 1
Pathophysiologic Markers (Not Routinely Used Clinically)
The UK guidelines identify key pathophysiologic mediators in TEN but do not recommend their clinical use for treatment guidance 1:
- Granulysin (15-kDa secretory form): Present in high concentrations in TEN blister fluid and considered the key mediator of keratinocyte apoptosis
- TNF-α, IFN-γ, and inducible nitric oxide synthase: Proapoptotic molecules linking drug-induced immune responses to keratinocyte damage
- Soluble Fas ligand, perforin, and granzyme: Implicated in triggering programmed cell death
These markers are research tools, not clinical decision-making tools in current practice.
Emerging Research Biomarkers
Recent high-quality research (2025-2026) identifies several practical inflammatory markers that may guide treatment selection:
Complete Blood Count-Derived Ratios
The neutrophil-to-lymphocyte ratio (NLR) shows the most promise as a practical biomarker 2, 3:
- High baseline NLR in typical TEN: Associated with later onset of severe complications 3
- Decreasing NLR after treatment: Indicates beneficial treatment response in typical TEN 3
- NLR, dNLR, PLR, and NLPR: Independent risk factors for elevated SCORTEN scores 2
- MLR (monocyte/lymphocyte ratio): Independent prognostic factor for healing time 2
Critical caveat: For immune checkpoint inhibitor-related TEN (irTEN), the pattern is reversed—low baseline NLR and increasing NLR after treatment indicate poor outcomes 3. This distinction is essential for proper interpretation.
Cytokine Profiles for Treatment Selection
The most recent evidence (2026) suggests specific cytokine patterns can guide therapy choice after standard corticosteroid failure 4:
Baseline predictors of standard corticosteroid failure:
- Granulysin ≥1.6 ng/mL
- Soluble Fas ligand ≥2540 pg/mL
Treatment-specific cytokine responses:
- Standard corticosteroids: Inhibit both Th1 cytokines and monocyte-derived cytokines in responders
- Pulse corticosteroids: More efficiently reduce monocyte-derived cytokines than standard doses
- IVIG: Suppresses IFN-γ and IL-12p40 more efficiently than corticosteroids
- Plasmapheresis: Causes profound decrease in G-CSF and IL-10 with marked increase in IL-12
Acute Phase Reactants
C-reactive protein (CRP) and procalcitonin (PCT) are markedly elevated in SCADR 5:
- PCT higher in SJS/TEN than DRESS (0.85 vs 0.45 µg/L)
- CRP correlates positively with complement C3 (r=0.60)
- These help differentiate between SCADR subtypes but are not specific treatment guides
Humoral Immune Markers
SCADR patients show 5:
- Lower IgG (8.8±4.1 g/L vs controls)
- Lower complement levels (C3: 1.01±0.37 g/L; C4: 0.21±0.12 g/L)
Clinical Monitoring Approach
The UK guidelines recommend monitoring for sepsis using clinical signs rather than specific inflammatory markers 1:
Clinical indicators to monitor:
- Confusion, hypotension, reduced urine output, reduced oxygen saturation
- Increased skin pain (suggests cutaneous infection)
- Rise in CRP and neutrophilia
- Monoculture on swabs from multiple sites (indicates predominant organism)
Baseline investigations recommended 1:
- Full blood count, ESR, CRP
- Urea and electrolytes
- Liver function tests
- Coagulation studies
Practical Algorithm
For typical TEN:
- Baseline assessment: Obtain CBC with differential, calculate NLR, measure CRP
- If considering immunomodulation beyond supportive care: Check granulysin and sFasL if available (≥1.6 ng/mL and ≥2540 pg/mL predict standard corticosteroid failure) 4
- Monitor NLR serially: Decreasing values suggest treatment response 3
- If standard corticosteroids fail: Consider cytokine profiling to select between pulse corticosteroids, IVIG, or plasmapheresis based on predominant cytokine pattern 4
Critical pitfall: The guidelines emphasize that immunomodulatory therapy should only be administered under specialist supervision in the context of clinical research and/or case registry 6. The evidence base remains insufficient for routine use outside specialized centers.
The most important "marker" remains clinical assessment: extent of epidermal detachment (SCORTEN), progression of disease, and signs of systemic infection remain the primary drivers of management decisions 1.